What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ZE94-0605 is an investigational, selective CDK2 inhibitor supplied as oral capsules in 50 mg and 100 mg strengths. It is administered once daily with approximately 240 mL water in a fasted state (no food for at least 2 hours before or 1 hour after dosing), in continuous 28-day cycles at the cohort-assigned dose. Capsules are swallowed whole.”In the company’s words, NCT07524140 on ClinicalTrials.gov
- Main trialPhase 1
- “ZE94-0605 is an oral, selective cyclin-dependent kinase 2 (CDK2) inhibitor. This multicenter, open-label, first-in-human Phase 1 study will evaluate ZE94-0605 in adults with advanced, unresectable or metastatic solid tumors. Phase 1a will use sequential dose escalation to determine the maximally tolerated dose and biologically effective dose. Phase 1b will randomize participants with CCNE1 amplification between two dose levels to select the recommended Phase 2 dose.”In the company’s words, NCT07524140 on ClinicalTrials.gov
Other drugs for Advanced Solid Tumor Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- Jan 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jan 2028 | A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026